What does the SUMMIT tirzepatide trial programme actually show?

Is SUMMIT the same as SURMOUNT, and why does the spelling matter?

The two names are easy to conflate, and plenty of people do. They refer to separate but related research programmes into tirzepatide, each designed to answer different questions.

The SURMOUNT trials (SURMOUNT-1, SURMOUNT-2 and others) were the core weight-management studies that underpinned tirzepatide's UK licence for obesity. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity or overweight and at least one weight-related condition, running for 72 weeks. Average weight loss at the 15 mg dose reached roughly 20–21%, a figure that informed NICE's appraisal of tirzepatide (TA1026), published in December 2024.

SUMMIT is a different strand of the research. It studied tirzepatide in people with heart failure with preserved ejection fraction (HFpEF) and obesity, a population where excess weight makes cardiac function measurably worse. The primary endpoints were about exercise capacity and symptom burden, not weight loss itself, though meaningful weight reduction was observed as part of the effect. A separate kidney-outcomes study carried the SUMMIT name in an earlier phase of development.

If you have found results attributed to "SUMMIT tirzepatide" in a search, you are most likely reading about the heart-failure research, and our detailed breakdown of the SUMMIT study and its tirzepatide findings covers the cardiovascular outcomes more fully.

What did the SUMMIT heart-failure study actually find?

The SUMMIT HFpEF trial enrolled adults with heart failure with preserved ejection fraction and a BMI of 30 or above, a group where standard heart-failure medicines have historically offered limited relief. Participants received tirzepatide or placebo alongside existing treatment.

The trial reported improvements in exercise capacity (measured by peak oxygen uptake on cardiopulmonary testing) and in participants' self-reported symptoms and physical limitations on validated questionnaires. Participants on tirzepatide also lost a clinically significant proportion of body weight over the trial period, which is biologically consistent with the drug's mechanism: by acting on both GIP and GLP-1 receptors, tirzepatide reduces appetite, slows gastric emptying and improves several metabolic markers that contribute to cardiac strain in people living with obesity.

It is worth being precise about what this means for a reader considering tirzepatide for weight management: the SUMMIT data adds to prescribers' confidence in the medicine's safety and plausible wider benefits, but Mounjaro's UK licence for weight loss is grounded in the SURMOUNT weight-management programme. If you would like to explore the SUMMIT trial findings in more depth, our guide to the SUMMIT trial and tirzepatide's cardiovascular evidence sets out what the research showed and what it means in practice. A prescriber reviewing your eligibility is assessing you against that licensed indication. You can read more about how tirzepatide works mechanistically on our tirzepatide overview page.

Who qualifies for tirzepatide in the UK under the licensed criteria?

The UK licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition such as high blood pressure, dyslipidaemia, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under NICE guidance. A BMI number alone does not determine approval, the prescriber reviews the whole clinical picture, including existing conditions, medicines and any contraindications.

Treatment starts at 2.5 mg, which exists to let your system adjust rather than to produce significant weight change at that stage, and is titrated by the prescriber over subsequent months. The licensed schedule runs up to 15 mg, and if you want to understand how each dose tier behaves, our tirzepatide dosing guide walks through the levels in plain terms. Our full Mounjaro guide covers the titration schedule and what to expect at each stage.

NHS access follows NICE TA1026's phased rollout, currently limited to people with a BMI of 40 or above and four or more qualifying comorbidities, with broader cohorts being added through 2026 and 2027. Private prescription through a regulated pharmacy means no referral and no waiting list, subject to clinical suitability. If you are thinking about the cost side of that, our Mounjaro pricing page explains what a legitimate private prescription includes and the context behind current market prices.

What side effects does the SUMMIT and SURMOUNT evidence describe?

Across the tirzepatide trials, the most commonly reported side effects were gastrointestinal: nausea, loose stools, constipation, indigestion and burping. These were typically most noticeable after starting or after a dose increase, and in many participants they settled within a couple of weeks. Fatigue, headache and injection-site reactions were also reported.

The MHRA monitors tirzepatide under a Black Triangle (▼) designation, meaning it carries additional post-marketing surveillance requirements because it is a relatively new medicine. Pancreatitis is a known but uncommon serious risk: the MHRA issued a Drug Safety Update on this in January 2026, noting that severe, persistent stomach pain (especially if it reaches through to the back) warrants urgent medical attention. Any suspected side effects can be reported directly via the MHRA's Yellow Card scheme.

Tirzepatide is not recommended during pregnancy, while breastfeeding or for anyone actively trying to conceive. It is not licensed for under-18s. People with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use it. These are the kinds of factors a prescriber works through at consultation, the same-day clinical review at a regulated service like ours exists precisely to catch them. If you are ready to find out whether tirzepatide is appropriate for your situation, check your eligibility with our prescribers.

One practical note: if you are thinking about when to begin, treatment requests submitted before midday on a weekday (whether that is a Monday after a long weekend or the week before a bank holiday) are reviewed the same working day by a named GPhC-registered prescriber and dispatched with free next-working-day DPD delivery once approved.